• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NEK2是一种潜在的泛癌生物标志物和免疫治疗靶点。

NEK2 is a potential pan-cancer biomarker and immunotherapy target.

作者信息

Zhang Lanyue, Li Yang, Deng Juexiao, Liao Wenxin, Liu Tingting, Shen Fujin

机构信息

Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, 239 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.

出版信息

Discov Oncol. 2024 Nov 7;15(1):626. doi: 10.1007/s12672-024-01519-7.

DOI:10.1007/s12672-024-01519-7
PMID:39505744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11541068/
Abstract

BACKGROUND

NEK2 is a member of the NEKs family and plays an important role in cell mitosis. Increasing evidence suggests that NEK2 is associated with the development of multiple tumors, but systematic studies of NEK2 in cancer are still lacking. Therefore, we evaluated the prognostic value of NEK2 in 33 cancers to elucidate the potential function of NEK2 in pan-cancers.

METHODS

We investigated the role of NEK2 in pan-cancers utilizing The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. Additionally, we analyzed the association between NEK2 gene expression across various cancers, protein expression, the tumor microenvironment (TME), and drug sensitivity using several software and web platforms.The potential oncogenic role of NEK2 was initially explored using bioinformatics methods. Furthermore, we conducted in vitro experiments to preliminarily validate the function of NEK2 in cervical cancer.

RESULTS

NEK2 is overexpressed in almost all tumors, and mutation of NEK2 are associated with a poorer tumor prognosis. In addition, the correlation between NEK2 and immune features such as immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), Microsatellite instability(MSI) etc. suggest that NEK2 could potentially be applied in the immunotherapy of tumors.

CONCLUSION

NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy.

摘要

背景

NEK2是NEKs家族的成员之一，在细胞有丝分裂中发挥重要作用。越来越多的证据表明，NEK2与多种肿瘤的发生发展相关，但目前仍缺乏对NEK2在癌症中的系统性研究。因此，我们评估了NEK2在33种癌症中的预后价值，以阐明NEK2在泛癌中的潜在功能。

方法

我们利用癌症基因组图谱（TCGA）和基因型-组织表达（GTEx）数据库研究了NEK2在泛癌中的作用。此外，我们使用多种软件和网络平台分析了NEK2基因在不同癌症中的表达、蛋白质表达、肿瘤微环境（TME）以及药物敏感性之间的关联。最初使用生物信息学方法探索了NEK2的潜在致癌作用。此外，我们进行了体外实验，初步验证NEK2在宫颈癌中的功能。

结果

NEK2在几乎所有肿瘤中均过度表达，且NEK2突变与较差的肿瘤预后相关。此外，NEK2与免疫细胞浸润、免疫检查点基因、肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）等免疫特征之间的相关性表明，NEK2可能在肿瘤免疫治疗中具有应用潜力。

结论

NEK2可能是一种潜在的泛癌生物标志物和免疫治疗靶点，有助于提高肿瘤治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/84a69e83173a/12672_2024_1519_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/471febe2361d/12672_2024_1519_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/fbcc46ddabeb/12672_2024_1519_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/e22084f2fbb3/12672_2024_1519_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/e83d9f6f394e/12672_2024_1519_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/ecc14cb5ea8c/12672_2024_1519_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/5eeb632c811d/12672_2024_1519_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/95b72e504a68/12672_2024_1519_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/84a69e83173a/12672_2024_1519_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/471febe2361d/12672_2024_1519_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/fbcc46ddabeb/12672_2024_1519_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/e22084f2fbb3/12672_2024_1519_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/e83d9f6f394e/12672_2024_1519_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/ecc14cb5ea8c/12672_2024_1519_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/5eeb632c811d/12672_2024_1519_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/95b72e504a68/12672_2024_1519_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba2/11541068/84a69e83173a/12672_2024_1519_Fig8_HTML.jpg

相似文献

1
NEK2 is a potential pan-cancer biomarker and immunotherapy target.NEK2是一种潜在的泛癌生物标志物和免疫治疗靶点。
Discov Oncol. 2024 Nov 7;15(1):626. doi: 10.1007/s12672-024-01519-7.
2
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.鉴定SHCBP1作为一种潜在的生物标志物，涉及多种癌症的诊断、预后及肿瘤免疫微环境。
Comput Struct Biotechnol J. 2022 Jun 18;20:3106-3119. doi: 10.1016/j.csbj.2022.06.039. eCollection 2022.
3
A Pan-Cancer Analysis of the Oncogenic Role of : A Potential Biomarker for Prognosis and Immunotherapy.：一种潜在的预后和免疫治疗生物标志物的致癌作用的泛癌分析。 （注：原文冒号前内容不完整）
Front Genet. 2022 Jul 15;13:906174. doi: 10.3389/fgene.2022.906174. eCollection 2022.
4
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.对 33 种人类癌症的综合分析揭示了溶质载体家族 35 成员 A2 的临床意义和免疫治疗价值。
Front Immunol. 2023 May 18;14:1155182. doi: 10.3389/fimmu.2023.1155182. eCollection 2023.
5
CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.CXCL11 与免疫浸润相关，并影响患者免疫治疗疗效：泛癌分析。
Front Immunol. 2022 Jul 22;13:951247. doi: 10.3389/fimmu.2022.951247. eCollection 2022.
6
Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.泛癌中TGM3的临床和免疫学特征：一种潜在的预后生物标志物。
Front Genet. 2023 Jan 6;13:993438. doi: 10.3389/fgene.2022.993438. eCollection 2022.
7
Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation.鉴定 RNMT 为免疫治疗和预后生物标志物：从泛癌分析到肺鳞癌验证。
Immunobiology. 2024 Sep;229(5):152836. doi: 10.1016/j.imbio.2024.152836. Epub 2024 Jul 16.
8
POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.POC1A，癌症免疫抑制微环境的预后生物标志物。
Aging (Albany NY). 2022 Jun 23;14(12):5195-5210. doi: 10.18632/aging.204141.
9
Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.泛癌分析 PDIA3：鉴定其为肿瘤预后和免疫治疗的潜在生物标志物。
Oxid Med Cell Longev. 2022 Aug 22;2022:9614819. doi: 10.1155/2022/9614819. eCollection 2022.
10
is a candidate diagnosis, prognostic, and immunotherapeutic biomarker: a systematic pan-cancer analysis.是一种候选诊断、预后和免疫治疗生物标志物：一项系统性泛癌分析。
Transl Cancer Res. 2024 Feb 29;13(2):1026-1042. doi: 10.21037/tcr-23-1179. Epub 2024 Feb 1.

引用本文的文献

1
Multi-Omics Pan-Cancer Profiling of Unveils Its Prognostic Potential, Metabolic Regulation, and Immune Microenvironment Interactions.多组学泛癌分析揭示其预后潜力、代谢调控及免疫微环境相互作用。
Biology (Basel). 2025 May 19;14(5):567. doi: 10.3390/biology14050567.
2
NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury.NEK2抑制可减轻脂多糖诱导的内皮损伤。
ASPET Discov. 2025;1. doi: 10.1016/j.aspetd.2025.100002. Epub 2025 Mar 18.

本文引用的文献

1
Global cancer burden growing, amidst mounting need for services.全球癌症负担不断增加，对服务的需求也日益迫切。
Saudi Med J. 2024 Mar;45(3):326-327.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
TheMarker: a comprehensive database of therapeutic biomarkers.TheMarker：一个全面的治疗性生物标志物数据库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D1450-D1464. doi: 10.1093/nar/gkad862.
4
SingPro: a knowledge base providing single-cell proteomic data.SingPro：一个提供单细胞蛋白质组学数据的知识库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D552-D561. doi: 10.1093/nar/gkad830.
5
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.高表达的 NEK2 在髓系祖细胞中抑制多发性骨髓瘤中的 T 细胞免疫。
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
6
Cancer immunotherapies: advances and bottlenecks.癌症免疫疗法：进展与瓶颈。
Front Immunol. 2023 Aug 24;14:1212476. doi: 10.3389/fimmu.2023.1212476. eCollection 2023.
7
SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.SLC1A5 是一种与铁死亡和肿瘤微环境相关的新型生物标志物：泛癌症分析。
Aging (Albany NY). 2023 Aug 10;15(15):7451-7475. doi: 10.18632/aging.204911.
8
Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.前列腺癌中的免疫微环境浸润景观和免疫相关亚型。
Front Immunol. 2023 Jan 9;13:1001297. doi: 10.3389/fimmu.2022.1001297. eCollection 2022.
9
The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.2023 年的 STRING 数据库：针对任何感兴趣的测序基因组的蛋白质-蛋白质关联网络和功能富集分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. doi: 10.1093/nar/gkac1000.
10
NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes.NEK2 通过与 STRIPAK 复合物合作使 Hippo 通路失活，从而促进宫颈癌细胞的增殖。
Cancer Lett. 2022 Nov 28;549:215917. doi: 10.1016/j.canlet.2022.215917. Epub 2022 Sep 14.